Amylyx Pharmaceuticals
AMLX
AMLX
147 hedge funds and large institutions have $1.51B invested in Amylyx Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 60 increasing their positions, 36 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
3.69% more ownership
Funds ownership: 73.31% → 77% (+3.7%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
16% less capital invested
Capital invested by funds: $1.79B → $1.51B (-$286M)
Holders
147
Holding in Top 10
5
Calls
$56.4M
Puts
$31.4M
Top Buyers
| 1 | +$33.4M | |
| 2 | +$26.4M | |
| 3 | +$23.9M | |
| 4 |
D.E. Shaw & Co
New York
|
+$18.7M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$17.4M |
Top Sellers
| 1 | -$52.9M | |
| 2 | -$49.1M | |
| 3 | -$26.5M | |
| 4 |
DM
Deerfield Management
New York
|
-$20.8M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$20.3M |